


## 1,3-Dibromo-5,5-dimethylhydantoin

<b>Cat. No.:</b>	HY-Y0786		
<b>CAS No.:</b>	77-48-5		
<b>Molecular Formula:</b>	C <sub>5</sub> H <sub>6</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	285.92		
<b>Target:</b>	PROTAC Linkers		
<b>Pathway:</b>	PROTAC		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (349.75 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.4975 mL	17.4874 mL	34.9748 mL
	5 mM	0.6995 mL	3.4975 mL	6.9950 mL
	10 mM	0.3497 mL	1.7487 mL	3.4975 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

<b>Description</b>	1,3-Dibromo-5,5-dimethylhydantoin is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Alkyl-Chain
<b>In Vitro</b>	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. *EBioMedicine*. 2018 Oct;36:553-562

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA